ClinicalTrials.gg
RecruitingNCT07236099Updated Sep 14, 2026

Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

A Phase 2 interventional study of ICP-322 and Placebo in Prurigo Nodularis (PN), sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 43 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)

02

Conditions studied

  • Prurigo Nodularis (PN)

Browse trials for

03

In context

Prurigo

38 studies on the registry are indexed under Prurigo; 10 are open to participants now.

This study's planned enrollment of 135 is close to the median of 135 across 31 interventional studies indexed under Prurigo.

Browse Prurigo studies →

Lead sponsor

Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign forms before any procedure(s) are performed.
  2. Male or female aged between 18 and 75 years at the time of signing the informed consent.
  3. Clinical diagnosis of PN by a dermatologist for at least 3 months before the Screening visit.
  4. At least 20 pruriginous lesions on the entire body with a bilateral distribution (on both legs, and/or both arms and/or trunk) at both screening and the baseline (Day 1) visits.
  5. PP NRS score ≥ 7 at both screening and the baseline (Day 1) visits.
  6. IGA-CPG-S score ≥ 3 at both the screening and the baseline (Day 1) visits.
  7. History of inadequate response to topical of medium or higher potency or for whom topical treatments are otherwise medically inadvisable (e.g., because of important side effects or safety risks).

Willingness to avoid pregnancy or fathering children

Exclusion criteria

Exclusion Criteria:

  1. Patients with a documented AD severity moderate to severe presence of skin morbidities other than PN and mild AD that may interfere with the assessment of the study outcomes. PN secondary to medications .
  2. Any uncontrolled or serious disease, or any medical, psychological, or surgical condition including relevant laboratory abnormalities at screening that may either interfere with the interpretation of the clinical trial results and/or, in the investigator's judgment, would adversely affect the patient's participation in the study. Active chronic or acute infection participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
135 participants (estimated)

Study arms

  • Experimental
    ICP-332 80mg

    Drug: ICP-322

  • Experimental
    ICP-332 120mg

    Drug: ICP-322

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugICP-322

    ICP-322 Tablets

  • DrugPlacebo

    ICP-332 Placebo Tablets

06

What researchers measure

Primary outcomes

  1. Peak pruritus-numeric rate scale (PP NRS)

    Percent change from baseline of weekly average in Peak pruritus-numeric rate scale (PP NRS) at Week 16. Participants will be asked to rate their itch at the worst moment during the previous 24 hours. On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'.

    Time frame: Baseline to week 16

Secondary outcomes

  1. Improvement in PP NRS score

    Proportion of participants achieving ≥ 4-point improvement in PP NRS score (PP NRS ≥ 4) over time

    Time frame: Baseline through week 40

  2. Investigator's Global Assessment for Chronic Prurigo Stage scores of 0 or 1 (IGA-CPG-S 0/1)

    Proportion of participants achieving Investigator's Global Assessment for Chronic Prurigo Stage scores of 0 or 1 (IGA-CPG-S 0/1) over time

    Time frame: Baseline through week 40

  3. Dermatology Life Quality Index (DLQI)

    Change from baseline in Dermatology Life Quality Index (DLQI) score over time. The DLQI comprises 10 items assessing the impact of skin disease on patients' health-related quality of life (HRQoL) over the previous week. Overall scoring ranges from 0 to 30, with a high score indicative of a poor HRQoL

    Time frame: Baseline through week 40

  4. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Time frame: Baseline through week 40

  5. Maximum concentration (Cmax)

    Maximum concentration (Cmax) of ICP-322

    Time frame: Baseline through week 40

  6. Area Under Concentration Versus Time Curve (AUC)

    Area Under Concentration Versus Time Curve (AUC) of ICP-322

    Time frame: Baseline through week 40

07

Study locations

43 of 43 sites recruiting
  • Cahaba Dermatology and Skin Health Center
    Birmingham, Alabama 35244, United States
    Recruiting
    • Vlada Groysman · Contact
  • Medical Dermatology Specialists
    Phoenix, Arizona 85006, United States
    Recruiting
    • Lindsay Ackerman · Contact
  • Center for Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
    Recruiting
    • Sunil S Dhawan · Contact
  • Driven Research, LLC
    Miami, Florida 33126, United States
    Recruiting
    • Javier Alonso-Llamazares · Contact
  • Cordova Research Institute
    Sweetwater, Florida 33182, United States
    Recruiting
    • Maria Cartaya · Contact
  • Dawes Fretzin Clinical Research Group LLC
    Indianapolis, Indiana 46250, United States
    Recruiting
    • Kenneth W. Dawes · Contact
  • Oakland Hills Dermatology
    Auburn Hills, Michigan 48326, United States
    Recruiting
    • Christopher Buatti · Contact
  • The Derm Institute of West Michigan
    Caledonia, Michigan 49316, United States
    Recruiting
    • Kristi Hawley · Contact
  • Revival Research Institute, LLC
    Troy, Michigan 48084, United States
    Recruiting
    • Ali Moiin · Contact
  • Minnesota Clinical Study Center
    New Brighton, Minnesota 55112, United States
    Recruiting
    • Steven Kempers · Contact
  • Skin Specialists, PC
    Omaha, Nebraska 68144, United States
    Recruiting
    • Joel Schlessinger · Contact
  • StracSkin, PLLC
    Portsmouth, New Hampshire 03801, United States
    Recruiting
    • Abel Jarell · Contact
  • Apex Clinical Research Center
    Mayfield Heights, Ohio 44124, United States
    Recruiting
    • Jorge A Garcia-Zuazaga · Contact
  • International Clinical Research - Tennessee LLC
    Murfreesboro, Tennessee 37130, United States
    Recruiting
    • Christina Feser · Contact
  • The Second Affiliated Hospital of Wannan Medical University
    Wuhu, Anhui 241000, China
    Recruiting
    • Ruzhi Zhang · Contact
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100044, China
    Recruiting
    • Jianzhong Zhang · Contact
    • Cheng Zhou · Contact
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400016, China
    Recruiting
    • Tao Cai · Contact
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
    Recruiting
    • Niu Xiang · Contact
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong 510091, China
    Recruiting
    • Xiaohua Wang · Contact
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
    Recruiting
    • Guoqiang Zhang · Contact
  • Jingzhou Central Hospital
    Jingzhou, Hubei 434020, China
    Recruiting
    • Yi Sun · Contact
  • Xiangya Hospital of Central South University
    Changsha, Hunan 410008, China
    Recruiting
    • Juan Su · Contact
  • The first hospital of Jilin University
    Changchun, Jilin 130021, China
    Recruiting
    • Shanshan Li · Contact
  • Shenyang Seventh People's Hospital
    Shenyang, Liaoning 110003, China
    Recruiting
    • Zhen Wang · Contact
  • Shandong Provincial Dermatology Hospital
    Jinan, Shandong 250022, China
    Recruiting
    • Furen Zhang · Contact
  • Chengdu Second People's Hospital
    Chengdu, Sichuan 610021, China
    Recruiting
    • Yanyan Feng · Contact
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
    Recruiting
    • Lixia Zhang · Contact
  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
    Tianjin, Tianjin Municipality 300131, China
    Recruiting
    • Litao Zhang · Contact
    • Yan Xu · Contact
  • Affiliated Hangzhou First People's Hospital,School of Medicine ,Westlake University
    Hangzhou, Zhejiang 250022, China
    Recruiting
    • Liming Wu · Contact
  • Chu de Brest - Hopital Morvan
    Brest, 29690, France
    Recruiting
    • Laurent Misery · Contact
  • Uni Berlin Chartie Derma
    Berlin, 12203, Germany
    Recruiting
    • Martin Metz · Contact
  • Rosenpark Research
    Darmstadt, 64283, Germany
    Recruiting
    • Oliver Weirich · Contact
  • Uni Leipzig Derma
    Leipzig, 04103, Germany
    Recruiting
    • Jan-Christoph Simon · Contact
  • Dermatologischen Gemeinschaftspraxis Dres. Quist
    Mainz, 55128, Germany
    Recruiting
    • Seven Quist · Contact
  • Specderm Poznanska
    Bialystok, 15-375, Poland
    Recruiting
    • Maria Poznanska · Contact
  • AKK MEDlCAL Spółka z ograniczoną Odpowiedzialnością, Centrum Medyczne Tu się Leczy
    Gdansk, 80-280, Poland
    Recruiting
    • lzABELA KARAMoN · Contact
  • Zdybski Ned SP.Z.O.O
    Kielce, 25-553, Poland
    Recruiting
    • Jacek Zdybski · Contact
  • Amicare Centrum Medyczne
    Lodz, 91-495, Poland
    Recruiting
    • Aleksandra Bala-Wojsznis · Contact
  • Centrum Badawcze Panaceum
    Malbork, 82-200, Poland
    Recruiting
    • Anna Sobiezek-Kundro · Contact
  • Twoja Przychodnia
    Nowa Sól, 67-100, Poland
    Recruiting
    • Anna Kacalak-Rzepka · Contact
  • Twoja Przychodnia Centrum Medyczne
    Poznan, 60-324, Poland
    Recruiting
    • Leszek Bartoszak · Contact
  • Uniwersytecki Szpital Kliniczny
    Rzeszów, 35-055, Poland
    Recruiting
    • Adam Reich · Contact
  • Klinika Ambroziak Dermatologia
    Warsaw, 25-553, Poland
    Recruiting
    • Monika Kalowska · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Mar 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2025
First posted
Nov 19, 2025
StartActual
Nov 27, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Oct 2027
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07236099
Responsible party
Sponsor
First posted
Nov 19, 2025
Start date
Nov 27, 2025
Primary completion
Mar 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Sep 14, 2026

Study contacts

Alexia Lu
Contact
CO_HGRAC@innocarepharma.com
+86-010-66609745

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion